Silence Therapeutics plc
SLNCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $365 | $131 | $259 | $470 |
| - Cash | $121 | $54 | $66 | $99 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $244 | $77 | $194 | $371 |
| Revenue | $43 | $25 | $18 | $12 |
| % Growth | 70.5% | 45% | 41% | – |
| Gross Profit | $31 | $15 | $8 | $5 |
| % Margin | 72.7% | 59.3% | 46.8% | 39.9% |
| EBITDA | -$49 | -$50 | -$51 | -$45 |
| % Margin | -113.2% | -196.2% | -289.3% | -365.9% |
| Net Income | -$45 | -$43 | -$40 | -$39 |
| % Margin | -104.7% | -170.5% | -231.4% | -317.4% |
| EPS Diluted | -0.33 | -0.49 | -0.52 | -0.44 |
| % Growth | 32.7% | 5.8% | -18.2% | – |
| Operating Cash Flow | -$68 | -$39 | -$45 | $7 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | -$68 | -$39 | -$46 | $5 |